Deutsche Bank AG Has $584.31 Million Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)
Deutsche Bank AG increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 0.1% in Q1, owning 9,580,456 shares valued at $584.31 million. Other institutional investors also adjusted their holdings. Bristol Myers Squibb reported a quarterly EPS of $1.46, exceeding estimates, with revenue of $12.27 billion. The company declared a quarterly dividend of $0.62, yielding 5.5%. Analysts have mixed ratings on the stock, with an average target price of $56.38 and a consensus rating of "Hold."
Deutsche Bank AG grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 0.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,580,456 shares of the biopharmaceutical company's stock after purchasing an additional 13,995 shares during the period. Deutsche Bank AG owned about 0.47% of Bristol Myers Squibb worth $584,312,000 as of its most recent SEC filing.
- Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet
A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Pinney & Scofield Inc. purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at about $25,000. Park Square Financial Group LLC purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $26,000. Global Wealth Strategies & Associates boosted its stake in Bristol Myers Squibb by 137.5% in the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 275 shares during the period. Transce3nd LLC purchased a new position in Bristol Myers Squibb during the 4th quarter worth approximately $28,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Bristol Myers Squibb during the 1st quarter valued at $31,000. Institutional investors and hedge funds own 76.41% of the company's stock.
Get Bristol Myers Squibb alerts:
Bristol Myers Squibb Price Performance
NYSE BMY opened at $44.82 on Thursday. The stock has a 50-day simple moving average of $47.41 and a 200 day simple moving average of $52.06. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The stock has a market capitalization of $91.24 billion, a PE ratio of 18.07, a P/E/G ratio of 2.35 and a beta of 0.36. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.
- MarketBeat Week in Review – 02/03 - 02/07
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. The company had revenue of $12.27 billion during the quarter, compared to analyst estimates of $11.32 billion. During the same period in the previous year, the company earned $2.07 earnings per share. The company's quarterly revenue was up .6% compared to the same quarter last year. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.
Bristol Myers Squibb Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were given a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.5%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 100.00%.
Wall Street Analyst Weigh In
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
BMY has been the topic of a number of research analyst reports. Jefferies Financial Group lowered their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Piper Sandler initiated coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 target price on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of "Hold" and an average price target of $56.38.
Check Out Our Latest Analysis on BMY
Bristol Myers Squibb Profile
(Free Report)Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Read More
- Five stocks we like better than Bristol Myers Squibb
- Russell 2000 Index, How Investors Use it For Profitable Trading
- RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- How DigitalOcean's Focus Is Fueling Explosive Growth
- How to Invest in Blue Chip Stocks
- Can Celsius Stock Keep Its Momentum Going Any Longer?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Bristol Myers Squibb Right Now?
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
